Sandbox/intraabdominal: Difference between revisions

Jump to navigation Jump to search
Guillermo Rodriguez Nava (talk | contribs)
No edit summary
Guillermo Rodriguez Nava (talk | contribs)
No edit summary
Line 187: Line 187:
| valign=top |
| valign=top |
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
{| style="float: left; cellpadding=0; cellspacing= 0; width: 400px;"
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Sequential therapy}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Single agent}}
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''First 7 days'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Imipenem]]-[[Cilastatin]] 500 g IV q8h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Lansoprazole]] 30 mg q12h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Omeprazole]] 20 mg q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Meropenem]] 1 g IV q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Esomeprazole]] 40 mg q24h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Doripenem]] 500 g IV q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Rabeprazole]] 20 mg q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Piperacillin]]-[[Tazobactam]] 3.375 g IV q6h<sup>†</sup>'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin]] 1 g q12h'''''
|-
|-
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=center | '''''Next 7 days'''''
| style="padding: 0 5px; font-size: 90%; background: #F5F5F5;" align=left | <SMALL><sup>†</sup> For ''[[Pseudomonas aeruginosa]]'' may be increased to 3.375 g q4h or 4.5 g q6h .</SMALL>
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[PPI]] standard dose'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin]] 1 g q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Clarithromycin]] 500 mg q12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazol]] 500 mg q12h'''''
|-
|-
|}
|}
Line 232: Line 212:
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Third line treatment}}
! style="height: 30px; line-height: 30px; background: #4479BA; border: 0px; font-size: 100%; text-shadow: 0 -1px 0 rgba(0, 0, 0, 0.5);" align=center| {{fontcolor|#FFF|Third line treatment}}
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Rifabutin]] 150 mg q2h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Cefepime]] 2 g IV q8-12h'''''
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ceftazidime]] 2 g IV q8h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 400 g IV q12h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Amoxicillin]] 1 g IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | OR
 
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Levofloxacin]] 750 mg IV q24h'''''
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | PLUS
|-
|-
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Ciprofloxacin]] 500 mg/kg IV q12h'''''
| style="font-size: 90%; padding: 0 5px; background: #DCDCDC;" align=left | ▸ '''''[[Metronidazole]] 500 mg IV q8-12h or 1.5 g q24h'''''
|-
|-
|}
|}
|}
|}
|}
|}

Revision as of 15:45, 12 June 2014

Pediatric patients

  ▸  Single agent

  ▸  Combination

Adults, mild-to-moderate severity

  ▸  Single agent

  ▸  Combination

Adults, high risk or severity

  ▸  Single agent

  ▸  Combination

Single agent
Ertapenem 3 months to 12 years 15 mg/kg IV q12h; >13 years 1 g IV q24h
OR
Meropenem 60 mg/kg/day IV q8h
OR
Imipenem/Cilastatin 60-100 mg/kg/day IV q4-6h
OR
Ticarcillin-Clavulanate 200-300 mg/kg/day IV q12h
OR
Piperacillin-Tazobactam 200-300 mg/kg/day IV q6-8h
Combination
Ceftriaxone 50-70 mg/kg/day IV q12-24h
OR
Cefotaxime 150-200 mg/kg/day IV q6-8h
OR
Cefepime 100 mg/kg/day IV q12h
OR
Ceftazidime 150 mg/kg/day IV q8h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Gentamicin 3-7.5 mg/kg/day IV q2-4h
OR
tobramycin 3-7.5 mg/kg/day IV q8-24h
PLUS
Metronidazole 30-40 mg/kg/day IV q8h
OR
Clindamycin 20-40 mg/kg/day IV q6-8h
WITH OR WITHOUT
Ampicillin 200 mg/kg/day IV q8-24h
Single agent
Cefoxitin 2 g IV q6h
OR
Ertapenem 1 g IV q24h
OR
Moxifloxacin 400 mg IV q24h
OR
Tigecycline 100 mg initial dose, then 50 mg IV q12h
OR
Ticarcillin-Clavulanic acid 200 mg/kg/day IV q6h
Combination
Cefazolin 1-2 g IV q8h
OR
Cefuroxime 1.5 g IV q8h
OR
Ceftriaxone 1-2 g IV q12-24h
OR
Cefotaxime 1-2 g IV q6-8h
OR
Ciprofloxacin 400 mg IV q12h
OR
Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h
Single agent
Imipenem-Cilastatin 500 g IV q8h
OR
Meropenem 1 g IV q8h
OR
Doripenem 500 g IV q8h
OR
Piperacillin-Tazobactam 3.375 g IV q6h
For Pseudomonas aeruginosa may be increased to 3.375 g q4h or 4.5 g q6h .
Third line treatment
Cefepime 2 g IV q8-12h
OR
Ceftazidime 2 g IV q8h
OR
Ciprofloxacin 400 g IV q12h
OR Levofloxacin 750 mg IV q24h
PLUS
Metronidazole 500 mg IV q8-12h or 1.5 g q24h